Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LHCGR | P22888 | 9/20 | 0.49 |
| ▸ | FSHR | P23945 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5034074 | 0.92 | LHCGR (0.51) | LHCGRFSHRTSHRMAP4K4GAA | |
| SCHEMBL4422529 | 0.90 | JAK3 (0.42) | LHCGRFSHRTSHRJAK3MAP4K4 | |
| SCHEMBL4422167 | 0.85 | LHCGR (0.55) | LHCGRFSHRTSHRLMNAALDH1A1 | |
| SCHEMBL4430421 | 0.84 | LHCGR (0.66) | LHCGRFSHRTSHRLMNAALDH1A1 | |
| SCHEMBL4425074 | 0.83 | LHCGR (0.45) | LHCGRFSHRTSHRMAP4K4 | |
| SCHEMBL5028843 | 0.82 | LHCGR (0.72) | LHCGRFSHRTSHR | |
| SCHEMBL4423875 | 0.81 | LHCGR (0.69) | LHCGRFSHRTSHR | |
| SCHEMBL4425814 | 0.80 | LHCGR (0.40) | LHCGRFSHRTSHRJAK3MAP4K4 | |
| SCHEMBL4423532 | 0.76 | MAP4K4 (0.51) | JAK3MAP4K4LMNAALDH1A1HTT | |
| SCHEMBL27502615 | 0.75 | LHCGR (0.50) | LHCGRFSHRTSHRMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618963-B2 | Bicyclic heteroaromatic compounds | N.V. ORGANON (NL) | 2009-11-17 | — | — | US | disclosed |
| EP-1886999-A2 | Bicyclic heteroaromatic compound | N.V. Organon (NL) | 2008-02-13 | — | — | EP | disclosed |
| US-20070197527-A1 | Bicyclic heteroaromatic compounds | N.V. ORGANON (NL) | 2007-08-23 | — | — | US | disclosed |
| US-7229990-B2 | Bicyclic heteroaromatic compounds | N.V. ORGANON (NL) | 2007-06-12 | — | — | US | disclosed |
| CN-1247594-C | Bicyclic heteroaromatic compounds | OKZO NOBEL N V (NL) | 2006-03-29 | — | — | CN | disclosed |
| CN-1462273-A | Bicyclic heteroaromatic compounds | OKZO NOBEL N V (NL) | 2003-12-17 | — | — | CN | disclosed |
| US-20030225113-A1 | Bicyclic heteroaromatic compounds | MERCK SHARP & DOHME B.V. (NL) | 2003-12-04 | — | — | US | disclosed |
| EP-1322651-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS | Akzo Nobel N.V. (NL) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002024703-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS | AKZO NOBEL N.V. (NL) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225113-A1 | Bicyclic heteroaromatic compounds | NR5A1, CYP19A1, FSHR | LHCGR 13/4885FSHR 3/4885TSHR 1000/4885 |
| US-20070197527-A1 | Bicyclic heteroaromatic compounds | NR5A1, CYP19A1, FSHR | LHCGR 10/4885FSHR 3/4885TSHR 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.